BACKGROUND: Microvascular hyperpermeability resulting from endothelial barrier dysfunction (EBD) is associated with worse clinical outcomes in trauma-induced hemorrhagic shock. We have previously shown that treatment with Tubastatin A (TubA), a histone deacetylase 6 inhibitor, improves outcomes in animal models of shock. In this study, we investigate whether TubA treatment may prevent trauma-related EBD.
T rauma-related injuries are the leading cause of death in individuals younger than 46 years. 1 Endothelial barrier dysfunction (EBD) might play a role in trauma-related morbidity and mortality. 2 In intact blood vessels, endothelial cells and the endothelial glycocalyx layer (EGL) provide a semipermeable barrier, through which fluid and solutes can move in a regulatable manner. 3, 4 The EBD-related endothelial hyperpermeability is known to cause hypovolemic shock, organ edema and poor tissue perfusion, leading to numerous adverse events, including acute lung injury (ALI), abdominal compartment syndrome and multiple-organ dysfunction syndrome (MODS). [5] [6] [7] [8] Trauma patients who survive the initial hemorrhagic shock (HS) often develop MODS, which contributes to trauma-related morbidity and mortality. 9, 10 Tissue hypoxia with anaerobic metabolism is considered a major contributor to the development of post-HS MODS. 11 Several pathophysiologic mechanisms work in concert to cause EBD. Increased paracellular permeability is a central event in EBD and can be caused by numerous physiologic conditions. [12] [13] [14] Specifically, stress-induced dysfunction of endothelial tight junctions (ETJ) complexes and cytoskeletal contraction causes paracellular gap formation, a key feature of EBD. [15] [16] [17] The ETJ complex function and endothelial cell contraction is modulated by multiple up-stream effectors, which in turn are modulated through a number of physiologic response mechanisms. 16 One of these effectors is hypoxia-inducible factor 1α (HIF-1α), which plays a role in EBD under hypoxic conditions, through cytoskeletal contraction and compromised ETJ integrity. 16, 17 Hypoxia-inducible factor 1α also exacerbates EBD through increased expression of myosin light chain kinase protein, vascular endothelial growth factor and inducible nitric oxide synthase. [18] [19] [20] Restoring perfusion to hypoxic tissue through fluid replacement is still the main focus of resuscitation therapies for HS, but this strategy is often unsuccessful because of impaired mitochondrial function. 11, 21 Our group has previously investigated the role of pharmacological resuscitation with histone deacetylase (HDAC) inhibitors in maintaining cellular viability and function during shock. 22 Shock can decrease an HDACmediated decrease in cellular acetylation, which affects the functions of numerous regulatory proteins and genes. 22, 23 In fact, pharmacological inhibition of HDACs has been shown to improve survival in rat and swine models of lethal HS. [24] [25] [26] [27] To date, 18 HDACs have been identified. 9 The HDAC6 is a mainly cytoplasmic enzyme which regulates pathways in many biological processes, including cytoskeletal rearrangement and cell-cell interaction. 28 Our group has previously shown that HDAC6 inhibition with Tubastatin A (TubA) leads to improved survival in a rat model of HS. 24 In this study, we sought to determine whether HS-induced ALI and EBD could be prevented by HDAC6 inhibition.
METHODS

Sublethal HS Protocol and Lung Tissue Harvest
Male Wistar-Kyoto rats (227-311 g) were purchased from Charles River Breeding Laboratories, Inc. (Chicago, IL). Animals were allowed food and water ad libitum.
Tubastatin A (70 mg/kg; Calbiochem, San Diego, CA) solution was prepared with dimethyl sulfoxide (1 μL per gram bodyweight; Sigma-Aldrich, St. Louis, MO) as solvent. Inhalation anesthesia was induced with 4% isoflurane (Abbott Laboratories, North Chicago, IL) mixed with air in an induction chamber. Between 0.8% and 1.5% isoflurane was delivered via nose cone, using a veterinary multichannel anesthesia delivery and vaporizer system (Kent Scientific Corporation, Torrington, CT). Body temperature was controlled using an automated heating pad. Local anesthesia was achieved by injection with bupivacaine (0.2 mL of 0.25%, APP Pharmaceuticals, LLC. Schaumburg, IL). Femoral artery cannulation with polyethylene 50 catheter (Clay Adams, Sparks, MD) was performed using a micro cutdown technique and was used for blood withdrawal and hemodynamic monitoring (Ponemah Physiology Platform; Gould Instrument Systems, Valley View, OH).
To eliminate any survival bias in tissue sample collection, a sublethal HS protocol was designed. Total blood volume was calculated (estimated total blood volume [mL] = weight [g] Â 0.06 [mL/g] + 0.77 mL), 29 and 40% volume was drawn over 10 minutes, followed by 30 minutes of unresuscitated shock. Next, rats were given either TubA (70 mg/kg, treatment group, n = 6) or vehicle (dimethyl sulfoxide, 1 μL/g, vehicle group, n = 4). No additional fluid resuscitation was administered. Rats were euthanized 6 hours post-HS, lung tissues were harvested, washed with cold saline, frozen in liquid nitrogen, and stored at −80°C. For microscopy, the tissue was paraffin fixed. Vehicle and treatment group tissues were compared with lung tissues from normal rats (control group, n = 3).
ALI Assessment
An independent pathologist, who was blinded to the study groups, assessed ALI through scoring of lung histologic injury. Hematoxylin-eosin-stained slides of lung tissues were scored from 0 to 4 to quantify increasing severity of leukocyte infiltration, hemorrhage and congestion, as previously published to generate composite ALI scores.
30,31
Cell Culture and Treatments
Tubastatin A (Calbiochem) was diluted in phosphate buffered saline (PBS) at a stock concentration of 500 μM aliquoted and frozen for later experiments. Human umbilical vein endothelial cells (HUVEC) (CC-2519; Lonza, Basel, Switzerland) were grown in EGM BulletKit medium (Lonza) in a humidified atmosphere of 95% air and 5% CO 2 . Cells were used for experiments from passages 3 to 8. After cells had reached 70% confluency, medium was exchanged with glucose-free Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 0.5% fetal bovine serum (FBS), with and without 15μM TubA. Cells subjected to normoxic conditions were placed in a humidified chamber with 95% air and 5% CO 2 . For anoxic treatment, HUVECs were placed in a MIC-101 modular incubator chamber (Billups-Rothenburg, Del Mar, CA), which was flushed with 5% CO 2 and 95% N 2 for 15 minutes, and maintained in a 37°C environment for 24 hours to 48 hours. The anoxic conditions for final testing were selected after a series of pilot experiments. Our goal was to stress the cells without a major impact on their actual viability, as proposed by Lee et al. 32 The study groups were (1) normoxia, (2) normoxia plus 15μM TubA, (3) anoxia, and (4) anoxia plus 15 μM TubA.
Monolayer Permeability Assay
Human umbilical vein endothelial cells were seeded onto Polyester Membrane Transwell-Clear Inserts (0.4-μm pore, 6.5-mm diameter; Corning Inc., Corning, NY), and exposed to the treatment once they were at 100% confluency (3 days after seeding) for 30 hours. Next, the medium in all inserts was replaced with DMEM with 0.5% FBS and 10 mg/mL fluorescein isothiocyanate conjugated albumin (66 kDa) (Sigma-Aldrich). Medium in the bottom well was replaced with DMEM with 0.5% FBS. After 1 hour, samples were carefully removed in triplicate from the bottom well and read in a fluorometer (FluorStar Optima, BMG Labtech; excitation, 485 nm; emission, 520 nm). All experiments were repeated six times.
Western Blot Analysis
Human umbilical vein endothelial cells were harvested after 24 hours of incubation and were prepared using a whole cell lysis buffer kit (BD Biosciences, Bedford, MA). Equal amounts of samples were added to each lane after determination of protein concentration using the bicinchoninic acid method. Proteins were detected using antibodies against acetylated α-tubulin (Lys40, 3971; Cell Signaling Technology Inc., Danvers, MA), and HIF-1α (HIF-1α, 3716, Cell Signaling Technology Inc.) and incubated with corresponding fluorescent conjugated secondary antibodies (Alexa Fluor Dyes, Molecular Probes; Life Technologies, Carlsbad, CA). Signals were obtained using Odyssey CLx Infrared Imaging System (LI-COR Biosciences, Lincoln, NE). The results were quantified using Image Studio Lite software (LI-COR Biosciences). Ac-tubulin experiments were repeated five times; HIF-1α experiments were repeated four times.
Glycocalyx Shedding Assay
After 48 hours of treatment, cell-culture supernatants were removed, centrifuged at 1,000g for 15 minutes and stored at −80°C. Samples were thawed immediately before analysis and assayed in triplicate for concentrations for human soluble (s) ICAM-1 using a quantitative enzyme-linked immunosorbent assay kit according to the manufacturer's protocol (Quantikine; R&D Systems Inc., Minneapolis, MN). Absorbance was set to 450 nm with wavelength correction set to 540 nm and 570 nm. Experiments were repeated three times for groups, 1, 2, and 4 and five times for group 3.
Statistical Analysis and Data Presentation
Data in figures are presented as group means ± SD. Continuous variables were tested for normal distribution using the Shapiro-Wilk test. Continuous variables between three or more groups were compared using the Kruskal-Wallis H test, and intergroup comparisons were conducted using the Dunn's multiple comparisons test. Statistical analysis was performed using IBM SPSS Statistics (version 19 for iOS, IBM Corporation, Armonk, NY). Figures were created using GraphPad Prism (version 6 for iOS, GraphPad Software, San Diego, CA).
RESULTS
ALI
Compared with vehicle control, treatment with TubA significantly attenuated ALI (mean ALI 3.25 and 1, respectively; p = 0.032) (Fig. 1) . There was no significant difference in ALI between normoxic control and treatment groups (1.33 and 1, respectively; p = 0.786). Hemorrhagic shock caused an increase in ALI that was not statistically significant (1.33 and 3.25, respectively; p = 0.400).
Monolayer Permeability Assay
A key feature of EBD is paracellular hyperpermeability. We therefore thought to assess monolayer permeability using a transwell assay of HUVEC monolayers after 30 hours normoxia or anoxia, with or without TubA. Anoxia caused a statistically significant mean permeability increase of 68.8% when compared with normoxic controls ( p = 0.004) (Fig. 2) . Treatment with TubA and anoxia caused a mean permeability increase of 5%, which was significantly less that anoxia alone ( p = 0.004). There was no significant difference in permeability between normoxic control and anoxia plus TubA groups (p = 0.240).
Tubulin Acetylation
We analyzed the concentrations of acetylated α-tubulin, a marker for HDAC6 inhibition (Fig. 3) . After 24 hours, treatment with TubA caused a 92-fold mean increase of acetylated α-tubulin levels in normoxic cells, compared with nontreated normoxic cells ( p = 0.008). TubA caused a 23-fold mean increase of acetylated α-tubulin levels in anoxic cells, compared with nontreated anoxic cells ( p = 0.008). There was a 68-fold mean increase in acetylated α-tubulin levels in treated anoxic cells, compared with nontreated normoxic cells ( p = 0.008). There was a nonsignificant threefold mean increase in nontreated anoxic cells, compared with nontreated normoxic cells ( p = 0.548).
Hypoxia-Inducible Factor 1α
As HIF-1α has been shown to play an important role in EBD, we assessed expression using Western blot (Fig. 3) . After 30 hours of anoxia treatment, there was a 188% mean increase in HIF-1α expression in nontreated cells, compared with nontreated normoxic cells ( p = 0.029). Treatment with TubA caused a 56% decrease in HIF-1α expression, compared with nontreated normoxic cells, which was a significantly lower expression than in nontreated anoxic cells ( p = 0.029). The 56% decrease in HIF-1α expression found in TubA-treated anoxic cells, compared with nontreated normoxic cells, was statistically significant ( p = 0.029).
Glycocalyx Shedding
A marker for glycocalyx shedding, sICAM-1, was quantified in cell culture supernatants (Fig. 4) . Forty-eight hours of anoxic insult induced a significant 175% mean rise in sICAM-1 concentration, compared to nontreated normoxic cells ( p = 0.036). Treatment with TubA and anoxia caused a 6% decrease in sICAM-1 concentration, which was significantly less than anoxia alone ( p = 0.036). The 6% decrease found in TubAtreated anoxic cells, compared with nontreated normoxic cells, was not statistically significant ( p = 0.700). 
DISCUSSION
Hemorrhagic shock is a major cause of death in the immediate posttraumatic hours. 1, 33 The current treatment for HS focus on replacing the lost blood, but this often fails to correct the cellular disturbances. 11, 21 For the military, the logistical challenges of the battlefield make large volume resuscitation impractical, and increasingly efforts are being focused on pharmacological adjuncts that can make resuscitation more effective, or even eliminate the need for pre-hospital fluid administration. 22 Our group has investigated pharmacological treatment with HDAC inhibitors as a promising treatment to maintain life under austere circumstances ("bridge" therapy during evacuation to higher levels of care). We have shown improved survival and significantly attenuated organ injury following treatment with nonselective HDACI in animal models of HS, polytrauma, sepsis, and traumatic brain injury. 22 In fact, we have just finished a federally funded phase 1 clinical trial (ClinicalTrials.gov Identifier: NCT01951560) to test valproic acid treatment (a nonselective HDACI), and are ready to start a phase 2 trial in trauma patients. Although effective, there are concerns related to the large doses of nonselective HDACI that are needed to achieve a biological effect. 22 Recently, more potent isoform specific HDACI have become available, and they offer the potential for using lower doses, and theoretically a better safety profile. However, isoformspecific inhibition of HDAC6 with Tubastatin A in trauma is a largely unstudied concept. It has previously been reported that HS-induced tissue damage occurs not only due to lack of tissue perfusion, but also due to impaired mitochondrial function, 11, 21 and ineffective oxidative phosphorylation. 34 Our group has previously shown that HDAC6-inhibition with TubA protects cells against HS-induced mitochondrial dysfunction. 24 The underlying mechanisms, however, remain poorly defined.
In this study, we have shown that hemorrhage causes ALI in rats, which has previously been linked with EBD as a causative mechanism. [35] [36] [37] We have also shown that treatment with Tubastatin A prevents hemorrhage-induced ALI, which offers a potential explanation for the beneficial outcomes reported previously. 24 To further elucidate the mechanisms by which traumainduced EBD is ameliorated, we designed an in-vitro model using HUVECs. We found that exposure of HUVECs to anoxia and hemorrhage-mimetic medium caused a significant increase in HIF-1α expression, with a consequential increase in monolayer permeability and glycocalyx shedding. Exposure of the anoxic cells to Tubastatin A prevented these effects. Taken together, these findings suggest that HDAC6 inhibition exerts a protective effect by maintaining the integrity of the vascular endothelium, with attenuation of downstream effects, such as ALI.
As previously mentioned, HIF-1α is known as an important cellular mediator of hypoxia-induced EBD. 17, 38 HIF-1α exerts this effect, at least in part, through pathways that compromise ETJ integrity. 17, 39 HIF-1α-induced cytoskeletal contraction along with decreased ETJ complex integrity leads to formation of paracellular gaps and consequential endothelial monolayer hyperpermeability. 16, 17, 40 The vascular endothelium is covered by a thin layer of glycoproteins and proteoglycans, the EGL. 4, 41 The EGL plays an important role as a regulatable barrier to transport of proteins, fluids, and inflammatory cells, as well as in coagulation and as a mechanotransducer of shear and pressure stress to the vascular wall. 4, 41, 42 Upon stimulation with proinflammatory cytokines, reactive oxygen species, complement activation products or endotoxin, the endothelium becomes activated and changes phenotype. 43 During endothelial activation, as in the setting of HS, the EGL is shed, the endothelium becomes procoagulant, upregulates cellular adhesion molecules, and vascular permeability is greatly enhanced. [43] [44] [45] [46] [47] Soluble ICAM-1 has been shown to be a marker of this physiologic mechanism in vitro. 48 Our study was designed as a proof-of-concept study, and therefore holds certain inherent limitations. For the in vitro experiments, we used cultured HUVECs due to their reliability and widely applied use as a laboratory model for the human endothelium in general. Cultured HUVECs form a homogenous and nonexchanging barrier. In an experimental setting, this provides for good reproducibility, but poor abstraction. Studies of cultured cells also do not allow for influences of factors such as paracrine functions of local auxiliary cells, and in vitro studies have shown that permeability of cultured monolayers is far greater than in vivo. 49 We addressed this issue by conducting in vivo as well as in vitro experiments, which showed consistent results. This consistency between microscopic and macroscopic levels mirror a previous study by Ramirez et al which showed that ischemia-reperfusion of in vivo microcannulated rat mesenteric venules indeed causes EBD. 50 Finally, we only tested the HIF-1α pathway as a mediator of EBD. Although HIF-1α is an important mediator of EBD, other pathways are certainly relevant and should be analyzed in the setting of HDAC6-inhibition.
In conclusion, our study demonstrates that HDAC6 inhibition with TubA prevents hemorrhage-induced ALI in rats. Additionally, we have shown that TubA prevents anoxia-induced EBD in vitro. We showed this through demonstration of ALI prevention in a rat model of sublethal HS, and prevention of endothelial monolayer hyperpermeability in an in vitro model of HS. Taken together, these findings may relate to our previously reported findings that HDAC6 inhibition improves survival in a lethal model of HS in rats. Our data suggest that HIF-1α plays a central role in mediating trauma-induced EBD, and inhibition of HIF-1α prevents the detrimental effects of hemorrhage. Our results indicate HDAC6 should be further studied as a promising target for inhibition in future posttraumatic pharmacological resuscitation therapies.
